For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb... ( WALTHAM Mass. ...)

HOME >> MEDICINE >> NEWS

For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia

Date:7/22/2009

WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia is low among rheumatoid arthritis agents. Rheumatologists are less satisfied with the agent when compared to tumor necrosis factor-alpha (TNF-alpha) inhibitors across the top drivers of perception such as inducing remission, improving symptoms and slowing the progression of structural damage. They are also less satisfied with Orencia's affordability and number of reimbursement restrictions compared to other rheumatoid arthritis brands.

In contrast, surveyed patients who are currently taking or have taken Orencia perceive the agent second best out of the nine surveyed brands. Patients are satisfied with Orencia because of its ability to eliminate symptoms and lessen disability when compared to TNF-alpha inhibitors. However, this high perception may be attributed to the fact that an overwhelmingly majority of Orencia patients have switched to the drug after failing treatment with a TNF-alpha inhibitor.

The new report entitled Brand Perceptions in Rheumatoid Arthritis also finds that Orencia's physician-targeted messages were the two least appealing messages among the surveyed agents. Instead of targeting key resonance drivers such as improving joint symptoms, slowing progression of joint damage and helping patients function in basic daily and social activities, Orencia's lowest-ranked message targets copays and insurance coverage.

Orencia's patient-targeted message of 'Oh, yes I can!' ranks first among patients. This message encompasses many of patients' key resonance drivers, emphasizing the ability to improve quality of life as well as being simple and easy to remember.

"O
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
2. Varian Medical Systems Receives 510(k) Clearance for Fast and Accurate Acuros(TM) Radiotherapy Treatment Planning Capability
3. Fractional co2 Laser Offers Cosmetic Treatments with Minimal Downtime For Melbourne Patients
4. Earlier HIV antiviral treatment can be cost effective in areas of limited resources
5. New Alzheimers Treatment Could Be on the Horizon
6. New strategy in tumor treatment
7. Earlier HIV Treatment Could Save Lives Worldwide
8. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
9. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
10. Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
11. Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India

Post Your Comments:

For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb...( WALTHAM Mass. ...),Health